Press
Webinar: A blockbuster drug candidate for devastating rare skin diseases
PC111 for Pemphigus and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Il biotech italiano sfida patologie rare e orfane
La Repubblica, 08.05.2025 - L'azienda nasce come spin-off dell'Università di Modena e Reggio Emilia e si occupa di ricerca contro il pemfigo e la sindrome di Stevens-Johnson. Download this post in PDF
Scinai signs an option agreement to acquire rare diseasecompany Pincell and its novel antibody for treating Severe Dermatological Conditions
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions Scinai files an application for Euro 12 million grant to fund the next stage of development Pincell’s monoclonal antibody,...
PinCell’s studies open up new indications for lead candidate
Two pre-clinical studies carried out by leading dermatologist Dr. Riichiro Abe, Professor and Chair of Dermatology at Niigata University, indicate that PC111 monoclonal antibody can ease Stevens-Johnson Syndrome by eliminating excess of circulating Fas ligand.Severe...
PinCell announces 2 successful in-vivo studies for breakthrough skin disease therapy
Proprietary transgenic mouse produces human form of FasL protein May 4, 2023 - MILAN - PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent...
PinCell announces the development of a key transgenic mouse model and the appointment of Dr. Antonino Amato as CEO
The biotechnology company has established a promising in-vivo platform for the development of its lead therapy, a monoclonal antibody that stops blistering in chronic skin conditions without suppressing the immune system. January 19, 2023 - MILAN - PinCell, a...
PinCell appoints veteran biotech and biopharma executives to Management Team and Board of Directors
The nominations follow a successful seed funding led by Sofinnova Partners MILAN, Italy - May 6, 2020 - PinCell, a biotechnology company developing novel therapies for rare dermatological diseases, announced today the appointment of Gabriella Camboni, M.D., as Chief...
Malattie rare, scoperta made in Modena
Il prof. Pincelli e la dottoressa Marconi hanno creato un farmaco contro il pemfigo che non deprime il sistema immunitario di Davide Berti - Gazzetta di Modena - 22.06.2015 - Ricerca, speranza e nuova cura. Sono queste le parole d’ordine. Due medici modenesi, il...
Pincell sul podio di Innova Day
Nell’ambito dell’iniziativa organizzata da Democenter e ateneo gli investitori hanno premiato una start-up dell’Università di Modena e Reggio Emilia - 12.01.2010 - Tra le tre imprese premiate dagli investitori all'interno di Innova Day, l'evento organizzato da...